Abstract Number: 40

Severe generalised cutaneous eruptions associated with the topical use of bufexamac

S. Saikal1, A. Harris1,2, J. Relic1, P. Chee1

Meeting: 2018 Dermcoll

Session Information

Date: -

Session Title: Contact Dermatitis Symposium

Session Time: -

Bufexamac is a topical non-steroidal anti-inflammatory drug available over the counter in Australia for the treatment of common dermatoses. There is dearth of evidence within the medical literature documenting its efficacy but an abundance detailing its ability to cause severe allergic contact dermatitis (ACD) and polymorphic cutaneous reactions away from the site of application (1). This has resulted in its unavailability in New Zealand, Japan, the European Union (including the UK), the United States of America and Canada.
We present a case series of severe generalised cutaneous eruptions secondary to the topical use of preparations containing bufexamac to highlight the risk of this medication and discuss its utility in Australia.
1. Pan, Y. and R. Nixon, Allergic contact dermatitis to topical preparations of bufexamac. Australas J Dermatol, 2012. 53(3): p. 207–10.